Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar Rhabdomyosarcomas
Top Cited Papers
- 15 July 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (14) , 6936-6946
- https://doi.org/10.1158/0008-5472.can-05-4578
Abstract
Alveolar rhabdomyosarcomas (ARMS) are aggressive soft-tissue sarcomas affecting children and young adults. Most ARMS tumors express the PAX3-FKHR or PAX7-FKHR (PAX-FKHR) fusion genes resulting from the t(2;13) or t(1;13) chromosomal translocations, respectively. However, up to 25% of ARMS tumors are fusion negative, making it unclear whether ARMS represent a single disease or multiple clinical and biological entities with a common phenotype. To test to what extent PAX-FKHR determine class and behavior of ARMS, we used oligonucleotide microarray expression profiling on 139 primary rhabdomyosarcoma tumors and an in vitro model. We found that ARMS tumors expressing either PAX-FKHR gene share a common expression profile distinct from fusion-negative ARMS and from the other rhabdomyosarcoma variants. We also observed that PAX-FKHR expression above a minimum level is necessary for the detection of this expression profile. Using an ectopic PAX3-FKHR and PAX7-FKHR expression model, we identified an expression signature regulated by PAX-FKHR that is specific to PAX-FKHR-positive ARMS tumors. Data mining for functional annotations of signature genes suggested a role for PAX-FKHR in regulating ARMS proliferation and differentiation. Cox regression modeling identified a subset of genes within the PAX-FKHR expression signature that segregated ARMS patients into three risk groups with 5-year overall survival estimates of 7%, 48%, and 93%. These prognostic classes were independent of conventional clinical risk factors. Our results show that PAX-FKHR dictate a specific expression signature that helps define the molecular phenotype of PAX-FKHR-positive ARMS tumors and, because it is linked with disease outcome in ARMS patients, determine tumor behavior. (Cancer Res 2006; 66(14): 6936-46)Keywords
All Related Versions
This publication has 54 references indexed in Scilit:
- Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoproteinOncogene, 2004
- Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomesProceedings of the National Academy of Sciences, 2004
- Sensitivity and specificity of five abundance estimators for high-density oligonucleotide microarraysBioinformatics, 2004
- PAX3-FKHR Transformation Increases 26 S Proteasome-dependent Degradation of p27Kip1, a Potential Role for Elevated Skp2 ExpressionPublished by Elsevier ,2003
- Microarray Analysis Detects Novel Pax3 Downstream Target GenesJournal of Biological Chemistry, 2001
- Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?British Journal of Cancer, 2001
- Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4Oncogene, 2000
- Rhabdomyosarcoma – working out the pathwaysOncogene, 1999
- #647 Upregulation of MET but not NCAM expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcomaJournal of Pediatric Hematology/Oncology, 1998
- Agreement among and within groups of pathologists in the classification of rhabdomyosarcoma and related childhood sarcomas. Report of an international study of four pathology classificationsCancer, 1994